In conclusion, our findings suggest that GNE987 can effectively inhibit the growth of GBM cells and promote apoptosis by downregulating transcription of oncogenes, thus suggesting that GNE987 may be a good therapeutic strategy for GBM and S100A16 may be a new target against GBM. This evidence concerns the gene S100A16 and glioblastoma.